Systemic antiviral consumption in Kazakhstan
- PMID: 40594290
- PMCID: PMC12217505
- DOI: 10.1038/s41598-025-05161-3
Systemic antiviral consumption in Kazakhstan
Abstract
There is a lack of studies from low- and middle-income countries on systemic antiviral consumption (SAC). This study aims to fill this gap by providing a comprehensive analysis of nationwide antiviral consumption trends in Kazakhstan over a period of 7 years. The defined daily doses per 1000 inhabitants per day approach was utilized. Time series analyses were applied to analyze historical trends in SAC, evaluate the impact of the coronavirus disease-19 (COVID-19) pandemic, and make future projections until 2030. The total SAC increased over the study period, with an annual growth rate of 10.24%. Overall, the antivirals that exhibited the most substantial increases in consumption after 2020 were anti-herpes, anti-HBV/HCV, and anti-influenza agents. Predictive modeling indicated that future expenditures on antivirals will remain stable in the hospital sector, both in absolute terms and per million population (pmp) rates, but are likely to increase in the community sector, both in absolute terms and pmp rates. The study's findings have important implications for public health policy and resource allocation.
Keywords: Antimicrobial stewardship; Antiviral agents; Consumption; Kazakhstan; Time series.
© 2025. The Author(s).
Conflict of interest statement
Declarations. Competing interests: The authors declare no competing interests. Ethical approval: The study protocol (submission 802/23112023) was reviewed by the Nazarbayev University Institutional Research Ethics Committee (NU-IREC), which granted exempt status on December 1, 2023.
Figures




Similar articles
-
Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.Health Technol Assess. 2006 Aug;10(28):iii-iv, xi-xiv, 1-183. doi: 10.3310/hta10280. Health Technol Assess. 2006. PMID: 16904047
-
Antibody tests for identification of current and past infection with SARS-CoV-2.Cochrane Database Syst Rev. 2022 Nov 17;11(11):CD013652. doi: 10.1002/14651858.CD013652.pub2. Cochrane Database Syst Rev. 2022. PMID: 36394900 Free PMC article.
-
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665. doi: 10.1002/14651858.CD013665.pub3. Cochrane Database Syst Rev. 2022. PMID: 35593186 Free PMC article.
-
Home treatment for mental health problems: a systematic review.Health Technol Assess. 2001;5(15):1-139. doi: 10.3310/hta5150. Health Technol Assess. 2001. PMID: 11532236
-
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320. Health Technol Assess. 2001. PMID: 12065068
References
-
- Alter, M. J. Epidemiology of viral hepatitis and HIV co-infection. J. Hepatol.44 (1 Suppl), 6–9 (2006). - PubMed
-
- Abenova, M., Shaltynov, A., Jamedinova, U., Ospanov, E. & Semenova, Y. The association between parental child vaccination refusal rate and the impact of mass vaccination against COVID-19 in kazakhstan: an interrupted time series analysis with predictive modelling of nationwide data sources from 2013 to 2022. Vaccines12 (4), 429. 10.3390/vaccines12040429 (2024). - PMC - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous